IMMX
Immix Biopharma Inc
NASDAQ · Biotechnology
$6.74
+0.79 (+13.28%)
Open$6.09
Previous Close$5.95
Day High$6.87
Day Low$6.06
52W High$10.76
52W Low$5.15
Volume—
Avg Volume516.5K
Market Cap356.92M
P/E Ratio46.24
EPS$0.20
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+77.7% upside
Current
$6.74
$6.74
Target
$11.98
$11.98
$7.05
$11.98 avg
$14.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 163.82M | 157.27M | 158.27M |
| Net Income | -44,702,535 | -44,556,024 | -43,506,106 |
| Profit Margin | -27.3% | -28.3% | -27.5% |
| EBITDA | -45,867,623 | -43,115,764 | -48,402,369 |
| Free Cash Flow | -22,695,190 | -23,234,474 | -24,663,069 |
| Rev Growth | +3.0% | +15.0% | +13.1% |
| Debt/Equity | 0.40 | 0.42 | 0.38 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |